Adderall XR Reinstated In Canada Following Successful Appeal By Shire
Executive Summary
Shire's successful appeal before a Health Canada committee to return Adderall XR (amphetamine) to the Canadian market is the first time a company has contested a drug revocation through the agency's appeals process
You may also be interested in...
Shire Adderall XR Sales Suspended In Canada; FDA Stands By “Black Box”
Differences between FDA and Health Canada's regulatory responses to adverse event reports for Adderall XR are likely to raise more questions about FDA's drug safety review process
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials